NEO1 AND NEO-EXT STUDIES: PHARMACODYNAMIC/EXPLORATORY BIOMARKER AND SAFETY ASSESSMENTS FOLLOWING REPEAT AVALGLUCOSIDASE ALFA DOSING FOR UP TO 4.5 YEARS IN PATIENTS WITH LATE-ONSET POMPE DISEASE
Publication
, Conference
Dimachkie, M; Barohn, R; Kishnani, P; Ladha, S; Mengel, KE; Pena, LDM; Sacconi, S; Van Damme, P; Vissing, J; Haack, KA; Chen, R; Fraser, PA ...
Published in: MUSCLE & NERVE
September 1, 2019
Duke Scholars
Published In
MUSCLE & NERVE
EISSN
1097-4598
ISSN
0148-639X
Publication Date
September 1, 2019
Volume
60
Start / End Page
S48 / S49
Location
Austin, TX
Publisher
WILEY
Conference Name
Annual Meeting of the American-Association-of-Neuromuscular-and-Electrodiagnostic-Medicine (AANEM)
Related Subject Headings
- Neurology & Neurosurgery
- 11 Medical and Health Sciences
Citation
APA
Chicago
ICMJE
MLA
NLM
Dimachkie, M., Barohn, R., Kishnani, P., Ladha, S., Mengel, K. E., Pena, L. D. M., … Schoser, B. (2019). NEO1 AND NEO-EXT STUDIES: PHARMACODYNAMIC/EXPLORATORY BIOMARKER AND SAFETY ASSESSMENTS FOLLOWING REPEAT AVALGLUCOSIDASE ALFA DOSING FOR UP TO 4.5 YEARS IN PATIENTS WITH LATE-ONSET POMPE DISEASE. In MUSCLE & NERVE (Vol. 60, pp. S48–S49). Austin, TX: WILEY.
Dimachkie, Mazen, Richard Barohn, Priya Kishnani, Shafeeq Ladha, Karl Eugen Mengel, Loren D. M. Pena, Sabrina Sacconi, et al. “NEO1 AND NEO-EXT STUDIES: PHARMACODYNAMIC/EXPLORATORY BIOMARKER AND SAFETY ASSESSMENTS FOLLOWING REPEAT AVALGLUCOSIDASE ALFA DOSING FOR UP TO 4.5 YEARS IN PATIENTS WITH LATE-ONSET POMPE DISEASE.” In MUSCLE & NERVE, 60:S48–49. WILEY, 2019.
Dimachkie M, Barohn R, Kishnani P, Ladha S, Mengel KE, Pena LDM, et al. NEO1 AND NEO-EXT STUDIES: PHARMACODYNAMIC/EXPLORATORY BIOMARKER AND SAFETY ASSESSMENTS FOLLOWING REPEAT AVALGLUCOSIDASE ALFA DOSING FOR UP TO 4.5 YEARS IN PATIENTS WITH LATE-ONSET POMPE DISEASE. In: MUSCLE & NERVE. WILEY; 2019. p. S48–9.
Dimachkie, Mazen, et al. “NEO1 AND NEO-EXT STUDIES: PHARMACODYNAMIC/EXPLORATORY BIOMARKER AND SAFETY ASSESSMENTS FOLLOWING REPEAT AVALGLUCOSIDASE ALFA DOSING FOR UP TO 4.5 YEARS IN PATIENTS WITH LATE-ONSET POMPE DISEASE.” MUSCLE & NERVE, vol. 60, WILEY, 2019, pp. S48–49.
Dimachkie M, Barohn R, Kishnani P, Ladha S, Mengel KE, Pena LDM, Sacconi S, Van Damme P, Vissing J, Haack KA, Chen R, Fraser PA, Hug C, Schoser B. NEO1 AND NEO-EXT STUDIES: PHARMACODYNAMIC/EXPLORATORY BIOMARKER AND SAFETY ASSESSMENTS FOLLOWING REPEAT AVALGLUCOSIDASE ALFA DOSING FOR UP TO 4.5 YEARS IN PATIENTS WITH LATE-ONSET POMPE DISEASE. MUSCLE & NERVE. WILEY; 2019. p. S48–S49.
Published In
MUSCLE & NERVE
EISSN
1097-4598
ISSN
0148-639X
Publication Date
September 1, 2019
Volume
60
Start / End Page
S48 / S49
Location
Austin, TX
Publisher
WILEY
Conference Name
Annual Meeting of the American-Association-of-Neuromuscular-and-Electrodiagnostic-Medicine (AANEM)
Related Subject Headings
- Neurology & Neurosurgery
- 11 Medical and Health Sciences